Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead's Epclusa: FDA Sought To Push Efficacy Bar Higher In Hepatitis C

Nov 25 2016

• By Sue Sutter

Liver infection

Related Content

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Nov 02 2016

Harvoni Approval Led To Narrowing Of Epclusa's Breakthrough Status

Nov 25 2016

Epclusa Clinical Development Timeline

Nov 25 2016

Epclusa Reviewers

Nov 25 2016

Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy

Jun 28 2016

Related Companies

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Additional Topics

Approvals Regulation Drug Review Profile BioPharmaceutical Infectious Diseases

More from Drug Review Profiles

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window